Introduction {#S0001}
============

Chronic obstructive pulmonary disease (COPD) is an independent risk factor for multiple comorbidities such as diabetes, coronary artery disease and hypertension.[@CIT0001],[@CIT0002] These comorbidities, which are associated with obesity, are a major cause of mortality in this population, particularly in mild to moderate COPD.[@CIT0003]--[@CIT0005] Studies report an increasing proportion of obese COPD patients, leading to major metabolic disorders.[@CIT0006] The liver regulates multiple inflammatory pathways and free-fatty acid transportation and is particularly sensitive to ectopic fat deposition causing Fatty Liver Disease (FLD).[@CIT0007] The increased risk of cardiovascular disease in subjects with this liver disorder is also well documented.[@CIT0008]--[@CIT0010] Main intermediary mechanisms of FLD (and its histological component steatosis) include insulin resistance, metabolic syndrome[@CIT0011] and some key features of COPD as reduced physical activity,[@CIT0012] low-grade inflammation, oxidative stress and hypoxia.[@CIT0013],[@CIT0014] Although hepatic steatosis is a continuous process, severe fat infiltration is considered to be present when 33% or more of liver tissue on a biopsy is infiltrated by fat (stage 2--3 in the steatosis grade of the NAFLD activity score).[@CIT0015] Liver density measured by computed tomography (CT) scan is a non-invasive surrogate of fat infiltration, with lower liver densities reflecting more fat infiltration and a liver density of 40 Hounsfield Units (HU) corresponding to a severe 30% fatty infiltration.[@CIT0016]--[@CIT0018] Chest CTs are often available in patients with COPD and allow the assessment of the liver density in most of the cases, representing a potential «add-on» for clinicians wanting to avert comorbidities. We used the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) cohort to document the prevalence of fatty liver infiltration in patients with COPD in comparison with healthy controls, and to explore, in the COPD population, the association with major cardiovascular comorbidities collected in ECLIPSE.

Materials and Methods {#S0002}
=====================

Population {#S0002-S2001}
----------

The multicenter, longitudinal ECLIPSE cohort study (Clinicaltrials.gov NCT00292552) was conducted to identify surrogate markers of COPD progression.[@CIT0019] 2164 current or ex-smokers (≥10 pack-years) with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2 to 4 and 582 smokers or never smokers with normal lung function who served as controls were recruited from 12 countries.[@CIT0020],[@CIT0021] Patients' characteristics, blood samples and pulmonary function tests were obtained at baseline. Chest CT-scan was performed on all participants with the following protocol: 120-kV peak, 40 mA, and 1.00- or 1.25-mm slice thickness, at full inspiration. All subjects on whom a valid CT-scan slice at T12-L1 was obtained, to assess liver mean CT attenuation, were included. Comorbidities and medical history were recorded at baseline with standardized questionnaires.[@CIT0019]

Liver Density Assessment {#S0002-S2002}
------------------------

Liver density was quantified by measuring mean organ attenuation in Hounsfield unit (HU) by the same investigator using the body composition analysis platform of the Institut universitaire de cardiologie et de pneumologie de Québec and a validated image analysis software (Slice-O-Matic, Tomovision, Montréal, Québec, Canada) according to standardized techniques.[@CIT0022],[@CIT0023] A standardized segmentation protocol was followed by the evaluator consisting in using an automated segmentation tool to identify the liver perimeter ([Figure 1](#F0001){ref-type="fig"}) and then manually remove all potential artefact such as the gall blatter or the portal vein. To ensure validity, a sample of all segmented images were randomly selected and redone by the same evaluator to assess for intra-observer variation. A second imaging expert segmented the same sample to evaluate inter-observer variation, showing an excellent inter-observer validity (Inter-Class Coefficient 0.98, mean absolute difference 0.96 HU, mean relative difference 1.01%).Figure 1Example of a computed tomography slice before (Panel A) and after segmentation (Panel B).

Statistical Analysis {#S0002-S2003}
--------------------

We compared the prevalence of severe steatosis (liver density \<40 HU) in COPD and controls using chi-square statistics. To document the association between liver density and cardiovascular comorbidities in COPD, patients with COPD were divided into quartiles of liver density. The quartiles 1 (lowest density, steatosis) and 4 (highest density, no steatosis, reference) were compared with logistic regression in order to evaluate the association (odds ratio) with coronary disease (CAD), diabetes, heart failure, hypertension and stroke. Unadjusted odds ratio (OR), age and sex adjusted OR (OR~a~) and age, sex and body mass index (BMI) adjusted OR (OR~ab~) were sequentially calculated. Available inflammatory markers were compared between quartiles using ANCOVA. All statistical analyses were performed using SAS 9.4 software (SAS Institute, Cary, NC, USA). A p-value \<0.05 was considered as significant.

Results {#S0003}
=======

Population and Liver Attenuation Between COPD and Controls {#S0003-S2001}
----------------------------------------------------------

We retrieved 1941 patients (1554 COPD and 387 controls) for whom a CT slice at T12-L1 could be analysed for liver attenuation ([Table 1](#T0001){ref-type="table"}). Patients with COPD were older (64±7 years vs 55±9 years; p\<0.001) and the proportion of men was greater (61% vs 57%; p\<0.001) than in controls. BMI was slightly but significantly lower in patients with COPD (26.1±5.2 kg/m^2^ in COPD vs 26.6±4.7 kg/m^2^ in controls; p= 0.046). All considered cardiovascular comorbidities were significantly more prevalent in patients with COPD. The proportion of subjects with severe liver steatosis (\<40 HU) was not different between COPD and controls (4.7% vs 5.2%, respectively, p=0.7). The distribution in hepatic densities ([Figure 2](#F0002){ref-type="fig"}) was similar between groups (p\>0.05 for all comparisons).Table 1Characteristics of Patients with COPD and Control SubjectsCOPD (n = 1554)Controls (n = 387)*p* value^†^Age (years)63.6 (0.2)55.0 (0.5)**\<0.001**BMI (kg/m^2^)26.1 (0.1)26.6 (0.2)**0.04**Liver attenuation (HU)58.7 (9.2)58.9 (9.0)0.61Male, n (%)948 (61)174 (45)**\<0.001Smoking status**Current smokers, n (%)575 (37.0)139 (36)**\<0.001**Former smokers, n (%)995 (64.0)93 (24.0)Never smokers, n (%)--155 (40.1)Pack/year48.4 (0.7)18.3 (1.1)**\<0.001Pulmonary Function**FEV~1~ (% pred)43.5 (0.4)108.0 (0.7)**\<0.001**FVC (L)2.77 (0.02)4.15 (0.05)**\<0.001**FEV~1~/FVC0.44 (0.01)0.77 (0.01)**\<0.001**GOLD stage 2, n (%)663 (42.7)--*--* 3, n (%)675 (43.4)--*--* 4, n (%)216 (13.9)--*--***Clinical variables**SGRQ total score49.2 (0.5)7.5 (0.6)**\<0.001**Hypertension, n (%)595 (38.3)23.0 (5.9)**\<0.001**Diabetes, n (%)138 (8.9)5.5 (1.4)**0.03**Coronary artery disease, n (%)361 (23.2)39 (10.0)**\<0.001**Heart failure, n (%)90 (5.8)3 (0.8)**\<0.001**Stroke, n (%)59 (3.8)6 (1.6)**0.03Death during follow-up (n)**139 (8.9)19 (4.9)**\<0.001**[^2][^3] Figure 2Liver attenuation distribution among patients with COPD and control subjects. *p*\>0.05 for all comparisons.**Abbreviation:** COPD, chronic obstructive pulmonary disease

Association with Cardiovascular Comorbidities and Cytokines Levels {#S0003-S2002}
------------------------------------------------------------------

The characteristics of the COPD population by quartile of liver density are presented in [Table 2](#T0002){ref-type="table"}. In the COPD population, compared to the reference quartile (mean attenuation 68 HU), the lowest hepatic density quartile (mean attenuation 46 HU) resulted in an unadjusted CAD OR=1.71 (95% CI 1.22 to 2.40), diabetes OR=2.96 (95% CI 1.753 to 5.007), heart failure OR=1.77 (95% CI 0.95 to 3.27), hypertension OR=1.58 (95% CI 1.17 to 2.14) and stroke OR=2.07 (95% CI 1.02 to 4.21). With age and sex adjustment, the association remains significant with CAD (OR~a~=1.59, 95% CI 1.12 to 2.24), diabetes OR=2.80 (95% CI 1.64 to 4.77), hypertension OR=1.66 (95% CI 1.22 to 2.25) and stroke (OR~a~=2.20, 95% CI 1.07 to 4.50). With age, sex and BMI adjustment, only stroke remained associated with low hepatic density (OR~ab~=2.35, 95% CI 1.11 to 4.98) ([Figure 3](#F0003){ref-type="fig"}, [[Supplementary Table S1](https://www.dovepress.com/get_supplementary_file.php?f=233834.docx)]{.ul}). In sub-group analysis by sex, an increased risk for all cardiovascular comorbidities was observed in women ([[Supplementary Tables S2 and S3](https://www.dovepress.com/get_supplementary_file.php?f=233834.docx)]{.ul}).Table 2Characteristics of COPD Patients by Liver Attenuation QuartileQuartile 1\
\[\< 54.6 HU\]\
(n=386)Quartile 2\
\[54.6 to 60.4 HU\]\
(n=391)Quartile 3\
\[60.4 to 64.9 HU\]\
(n=389)Quartile 4\
\[\> 64.9 HU\]\
(n=388)*p* value^†^Liver attenuation (HU)46.05 (0.40)57.90 (0.08)62.64 (0.07)68.32 (0.16)**\<0.001Demographics**Age63.8 (0.4)64.2 (0.3)63.0 (0.4)63.2 (0.4)0.07Sex (% male)270 (69.9)266 (68.0)210 (53.9)202 (52.1)**\<0.001**BMI28.6 (0.3)26.2 (0.3)25.0 (0.2)24.4 (0.2)**\<0.001**Current smokers (%)131 (33.9)133 (34.0)147 (37.8)163 (42)0.06Pack-year52 (2)48 (1)47 (1)47 (1)**0.04Pulmonary function**FEV1(% pred)44.8 (0.8)42.9 (0.8)42.5 (0.7)44.0 (0.8)0.13FVC (L)2.88 (0.04)2.85 (0.05)2.68 (0.04)2.66 (0.04)**\<0.001**FEV1/FVC0.45 (0.01)0.43 (0.01)0.43 (0.01)0.44 (0.01)0.06GOLD stage 2, n (%)176 (45,6)161 (41,2)156 (40,1)170 (43,8) 3, n (%)160 (41, 5)169 (43, 2)179 (46,0)167 (43,0)0.69 4, n (%)50 (13,0)61 (15,6)54 (13,9)51 (13,1)**Health status and functional tests**SGRQ score49 (1)49 (1)49 (1)50 (1)0.60mMRC score1.6 (0.1)1.7 (0.1)1.6 (0.1)1.7 (0.1)0.646MWT (m)361 (6)375 (7)384 (6)370 (6)0.08**Baseline comorbidities**Hypertension, n (%)168 (43.5)154 (39.5)150 (37.6)127 (32.7)**0.03**Diabetes, n (%)57 (14.7)36 (9.1)26 (6.6)21 (5.5)**\<0.001**Coronary artery disease, n (%)113 (29.2)97 (24.7)77 (19.4)75 (19.4)**\<0.01**Heart failure, n (%)30 (7.8)19 (4.8)23 (5.9)18 (4.6)0.21Stroke, n (%)24 (6.3)11 (2.9)12 (2.9)12 (3.2)**0.03Follow-up**Death, n (%)135 (35)160 (41)123 (31)124 (32)0.61Exacerbation rate (n by year)1.131.231.371.33**0.04**[^4][^5] Figure 3Unadjusted and adjusted odds ratios to present cardiovascular comorbidity in the lowest liver density quartile vs the highest liver density quartile.

Among inflammatory markers, interleukin-6 and C Reactive Protein (CRP) were significantly higher in quartile 1 compared to quartile 4, with a clear dose--response effect (CRP and IL6 significantly decreasing with increase in hepatic density) ([Figure 4](#F0004){ref-type="fig"}). Similar conclusion was reached when the analysis was stratified based on BMI (data not shown).Figure 4Inflammatory marker levels showing differences according to liver attenuation groups (**A**-**D**). Values are expressed with mean ± standard errors. 1 is the group with the lowest liver attenuation and 4 the group with the greatest liver attenuation. *p*-value for ANCOVA corrected for age, sex, Body Mass Index and smoking status.**Abbreviations:** CRP, C-reactive protein; IL6, and interleukin-6.

Discussion {#S0004}
==========

Despite the potential two-way relationship between COPD and liver steatosis due to chronic low-grade inflammation, intermittent hypoxia and induced adipokines,[@CIT0024],[@CIT0025] few data are available to draw an epidemiologic picture of liver steatosis in this population. In a previous study,[@CIT0026] we reported that the liver fibrosis stage of non-alcoholic fatty liver disease, but not steatosis, is an independent factor of cardiovascular morbidity in COPD, in line with results in the general population.[@CIT0027],[@CIT0028] The present study is the first large multinational COPD cohort with controls to report liver density prevalence. The ECLIPSE data show a similar liver density distribution between COPD and controls. Our results are at variance with previous studies where the prevalence of steatosis ranging from 30% to 41% was reported in COPD[@CIT0024],[@CIT0025] and found to be higher than the reported 5% to 20% prevalence in the general population.[@CIT0017],[@CIT0029],[@CIT0030] These discrepancies are likely related to the use of different diagnostic tools across studies, including biological scores and transient elastography[@CIT0031] which have the ability to detect milder fatty infiltration compared to CT scan.

Although CT-scan has its limitations in the assessment of fatty liver disease,[@CIT0032] this modality has the advantage of being widely available in pulmonary patients and nevertheless provides a reliable assessment of severe steatosis when liver density is \<40 HU.[@CIT0032] Furthermore, our purpose was to assess the relevance of this surrogate marker for cardiovascular comorbidities in COPD, which are the main known complications of fatty liver disorders.[@CIT0008],[@CIT0009] CT is also a less invasive alternative to liver biopsy, the gold standard to diagnose FLD, which is a costly procedure,[@CIT0033] prone to minor side-effects such as pain, or more severe complications, including a risk of death of 0.03%.[@CIT0034] Moreover, intra and interobserver variabilities exist in the quantification of FLD from a biopsy.[@CIT0035] Noninvasive tests (including biological scores and imaging) are cheaper, more easily repeatable, and lead to less interobserver variability, severe adverse events, refusal and bias than biopsy.[@CIT0034]

Using imaging data already available to the clinicians, screening for FLD could be performed in several patients with COPD. There are currently two methods to assess liver density from a CT scan. In the present investigation, we measured the mean organ attenuation with standardized segmentation which is more complex compared to the multiple region of interest (ROI) methods,[@CIT0017] but encompasses a larger area of evaluation which may improve the assessment in case of focal fatty infiltration.[@CIT0036],[@CIT0037] In our experience, there is little variation between these techniques as long as they are performed on non-enhanced CT.[@CIT0017] We thus recommend the ROI method in clinical practice, mostly because it is less time-consuming than calculating liver attenuation with standardized segmentation and available with current commercial software.

Sexual dimorphism concerns both NAFLD and cardiovascular comorbidities,[@CIT0038],[@CIT0039] and hormonal modulation is a key element to understand variations in risk by age and sex.[@CIT0040],[@CIT0041] Premenopausal women seem to be protected from developing high levels of NAFLD, while ovarian senescence appears to be associated with severe steatosis and fibrosing NASH. Due to an age \>40 yo in the COPD population, we could expect more or equal risk of steatosis in women than men. In ECLIPSE, women were less frequently exhibiting low liver density (steatosis), but low liver density in women resulted in stronger association with cardiovascular comorbidities than in men.

Among its potential limitations, the ECLIPSE study did not prospectively assess alcohol consumption, which prevents us from differentiating between FLD and Nonalcoholic fatty liver disease (NAFLD) or to suggest a precise origin for steatosis. However, this limitation should not question the link that we found between liver density with cardiovascular comorbidities because hepatic steatosis leads to worse cardiovascular status, irrespective of the underlying etiology.[@CIT0042] In the same way, we were not able to test the effect of some medications associated both with cardiovascular outcomes and fatty liver infiltration, like amiodarone.

Recent data showed that more advanced forms of NAFLD, namely fibrosis rather than steatosis are associated with cardiovascular events.[@CIT0026]--[@CIT0028] Unfortunately, in the ECLIPSE cohort, no evaluation of liver fibrosis is available, and biological data do not include transaminases, which makes the evaluation by non-invasive NAFLD scores impossible.

The short follow-up of this cohort (3 years) also prevents us from considering the impact of hepatic density on prospective cardiovascular events, due to the limited number of such events during the study period. Finally, the representativeness of the ECLIPSE cohort in relation to the different COPD phenotypes is questionable. Previous studies have tried to identify different phenotypes of COPD patients: frequent exacerbators;[@CIT0020],[@CIT0043] eosinophilic patients and asthma-COPD overlap syndrome;[@CIT0044],[@CIT0045] and patients with severe airflow limitation at the opposite of those with milder airflow limitation but with obesity and cardiovascular comorbidities.[@CIT0046] This last phenotype is the most likely to present both hepatic and cardiovascular comorbidities. Interestingly, in ECLIPSE, patients with GOLD 2 or 3 COPD and a body mass index \>30 kg/m^2^ only represented 17% (266/1554) of COPD patients, which could appear low in an occidental population.[@CIT0006],[@CIT0047],[@CIT0048]

Conclusion {#S0005}
==========

The present data indicate that a low liver density emerged as a predictor of cardiovascular comorbidities, particularly stroke, in COPD. Although we cannot conclude definitively on the clinical implications of liver steatosis in COPD, this comorbidity is likely relevant considering its association with chronic liver disease and metabolic comorbidities such as insulin resistance, ectopic fat accumulation, and lipid abnormalities.
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